RxDoctor Payments Data

Alexander Meyer, MD

Interventional Cardiology · Walnut Creek, CANPI 1639533359

Payments from drug & device makers

$2,093in general payments, 2019–2025

Across 47 payments — averaging $44.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$992
  • AstraZeneca$304
  • Abiomed$113
  • Shockwave Medical, Inc$112
  • Medtronic$91
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$79
  • plus $402 from 13 others

What the payments were for

  • Food & beverage$1,91892%
  • Education$1758%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,093 in reported general payments places this provider in the 20th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$67,599
Medicare patients
248
Services billed
596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$121,722
JardianceEmpagliflozin54$67,004
XareltoRivaroxaban24$29,047
EntrestoSacubitril/Valsartan24$22,979
Repatha SureclickEvolocumab19$14,555
NexletolBempedoic Acid13$8,099
Metoprolol Succinate169$2,231
ClopidogrelClopidogrel Bisulfate103$1,324
Atorvastatin Calcium93$1,088
Ezetimibe26$936
Rosuvastatin Calcium49$562
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$486
Potassium Chloride18$466
Isosorbide Mononitrate ErIsosorbide Mononitrate24$439
Nitroglycerin17$398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$46$67,00454 claims
Johnson & JohnsonXarelto$37$29,04724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →